Roger Dansey
Director/Board Member at INOVIO PHARMACEUTICALS, INC.
Net worth: 20 953 $ as of 31/10/2025
Profile
Presently, Roger D. Dansey occupies the position of Chief Medical Officer for Seagen Inc. In the past Dr. Dansey held the position of Vice President-Oncology Clinical Research at Gilead Sciences, Inc. and SVP & Head-Therapeutic Area at Merck Research Laboratories Massachusetts LLC. Dr. Dansey received a doctorate from the University of the Witwatersrand.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 21/05/2025 | 8,916 ( 0.02% ) | 20 953 $ | 31/10/2025 | |
| 06/11/2025 | 0 ( -.--% ) | - $ | 31/10/2025 |
Latest news about Roger Dansey
Roger Dansey active positions
| Companies | Position | Start |
|---|---|---|
| INOVIO PHARMACEUTICALS, INC. | Director/Board Member | 13/05/2021 |
| BICYCLE THERAPEUTICS PLC | Director/Board Member | 08/09/2025 |
| NURIX THERAPEUTICS, INC. | Director/Board Member | 10/11/2025 |
Inovio, Inc.
Inovio, Inc. Packaged SoftwareTechnology Services Operates as an online payment platform | Director/Board Member | - |
Ultrahuman Eight Ltd.
Ultrahuman Eight Ltd. Manufactures cancer-related medicine | Director/Board Member | - |
Shasqi, Inc.
Shasqi, Inc. Operates as a biopharmaceutical company | Director/Board Member | - |
Former positions of Roger Dansey
| Companies | Position | End |
|---|---|---|
| KRONOS BIO, INC. | Director/Board Member | 20/06/2025 |
| PFIZER INC. | Corporate Officer/Principal | 05/02/2025 |
| SEAGEN INC. | Chief Executive Officer | 09/11/2022 |
| ░░░░░ ░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░ ░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Roger Dansey
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 13 |
|---|---|
Gilead Sciences, Inc.
Gilead Sciences, Inc. Discovers, develops and commercializes therapeutic products and treatments for life threatening diseases | |
Merck & Co., Inc.
Merck & Co., Inc. Manufactures human and animal health pharmaceutical products & vaccines | |
Pfizer Inc.
Pfizer Inc. Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | |
Seagen, Inc.
Seagen, Inc. Pharmaceuticals: MajorHealth Technology Develops monoclonal antibody-based therapeutic products for the treatment of cancer and immunologic diseases | Health Technology |
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. Operates as a a clinical stage biopharmaceutical company that discovers, develops and commercializes oral, small molecule therapies for the treatment of cancer & immune disorders | |
Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops synthetic vaccines and immune therapies for cancers and infectious diseases | Health Technology |
University of the Witwatersrand
University of the Witwatersrand Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Merck Research Laboratories Massachusetts LLC
Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Health Technology |
Inovio, Inc.
Inovio, Inc. Packaged SoftwareTechnology Services Operates as an online payment platform | Technology Services |
Bicycle Therapeutics Plc
Bicycle Therapeutics Plc BiotechnologyHealth Technology Develops chemically synthesized medicines | Health Technology |
Kronos Bio, Inc.
Kronos Bio, Inc. Operates as a clinical-stage biopharmaceutical company that develops novel cancer therapeutics | |
Shasqi, Inc.
Shasqi, Inc. Operates as a biopharmaceutical company | |
Ultrahuman Eight Ltd.
Ultrahuman Eight Ltd. Manufactures cancer-related medicine |
- Stock Market
- Insiders
- Roger Dansey
















